Table 4 Initiation of advanced and other therapies (17–21)
No. | Statement | Agreement (%) |
|---|---|---|
17 | Access to biologic therapies for patient (when indicated) is fundamental to improving outcomes in severe asthma in Canada | 97 |
18 | The choice of biologic therapies should be driven by phenotyping, which includes clinical history (e.g., triggers, age of onset), comorbidities, biomarkers and spirometry | 100 |
19 | Future Canadian severe asthma guidelines should include pragmatic and practical guidance on the initiation and choice of biologic therapies for severe asthma | 97 |
20 | Once a patient has been approved for an advanced therapy, initiation of treatment should not be delayed by more than 2 weeks | 90 |
21 | Once a patient has been approved for an advanced therapy, initiation of treatment should not be delayed by more than 4 weeks | 91 |